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Neuropathic pain is a chronic debilitating disease
characterized by mechanical allodynia and sponta-
neous pain. Because symptoms are often unrespon-
sive to conventional methods of pain treatment, new
therapeutic approaches are essential. Here, we
describe a strategy that not only ameliorates symp-
toms of neuropathic pain but is also potentially
disease modifying. We show that transplantation of
immature telencephalic GABAergic interneurons
from the mouse medial ganglionic eminence (MGE)
into the adult mouse spinal cord completely reverses
the mechanical hypersensitivity produced by periph-
eral nerve injury. Underlying this improvement is
a remarkable integration of the MGE transplants
into the host spinal cord circuitry, in which the trans-
planted cells make functional connections with
both primary afferent and spinal cord neurons. By
contrast, MGE transplants were not effective against
inflammatory pain. Our findings suggest that MGE-
derivedGABAergic interneurons overcome the spinal
cord hyperexcitability that is a hallmark of nerve
injury-induced neuropathic pain.
INTRODUCTION
Loss of spinal cord dorsal horn inhibitory circuits, many of which
involve interneurons that express gamma aminobutyric acid
(GABA), is one of the major contributors to the persistent neuro-
pathic pain that can follow nerve injury. The loss of inhibition
contributes not only to the development of spontaneous pain
but also to the hyperexcitability that underlies the mechanical
hypersensitivity (allodynia) and exacerbated pain (hyperalgesia).
For example, partial sciatic nerve injury reduces spinal GABArelease and expression of the GABA-synthesizing enzyme gluta-
mic acid decarboxylase (GAD; Moore et al., 2002). The conse-
quence of this is a loss of inhibitory tone in the dorsal horn. It is
not clear, however, whether the reduced GABAergic inhibition
results from injury-induced degeneration of GABAergic interneu-
rons (Scholz et al., 2005; Sugimoto et al., 1990), reduced primary
afferent input to these interneurons (Kohno et al., 2003; Polga´r
and Todd, 2008), decreased release of GABA (Lever et al.,
2003), or downregulation of GABA, GAD, or pre- and postsyn-
aptic GABA receptors (Castro-Lopes et al., 1993; Eaton et al.,
1998; Fukuoka et al., 1998; Ibuki et al., 1997; Polga´r et al., 2004).
Not surprisingly, many pharmacological approaches to
managing nerve injury-induced neuropathic pain enhance inhib-
itory controls. Indeed, significant analgesia can be achieved by
activating spinal GABAA or GABAB receptors in various models
of inflammatory and neuropathic pain (Asiedu et al., 2010; Knabl
et al., 2008; Munro et al., 2009). The pharmacological regulation
of GABA controls, however, is not straightforward. For example,
some patients do not respond to these therapies and adverse
side effects, which result from systemic drug administration,
are dose limiting. Here, we describe a potentially disease-modi-
fying therapeutic approach designed to restore the inhibitory
tone in the spinal cord. This approach consists of transplanting
embryonic GABAergic neuronal precursors in the dorsal horn
of the spinal cord.
Previous studies reported that embryonic GABAergic cortical
interneuron precursors from the medial ganglionic eminence
(MGE) grafted into adult forebrain disperse and synaptically inte-
grate into functional circuits (Baraban et al., 2009; Southwell
et al., 2010; Wichterle et al., 1999). These grafts are effective in
different neurological disorders associated with neuronal hyper-
excitability, for example, animal models of epilepsy (Alvarez-
Dolado et al., 2006; Baraban et al., 2009; Calcagnotto et al.,
2010; Martı´nez-Cerden˜o et al., 2010). Here, we asked whether
MGE transplants are also viable in the spinal cord, which is
outside of their natural environment. We then investigated
whether MGE cells can receive and form connections within
local circuits of the host dorsal horn. Finally, we assessed theNeuron 74, 663–675, May 24, 2012 ª2012 Elsevier Inc. 663
Figure 1. MGE-Derived Transplants Are Viable in the Spinal Cord of Naive Adult Mice
MGE-derived cells constitutively express GFP (green).
(A and B) One day after transplantation, the transplant consisted of an aggregate of GFP+ MGE cells at or near the injection site. Occasionally, we observed
isolated cells that migrated from the injection site as well as cells at the surface of the cord (arrows in B). The transplants were injected unilaterally, and we never
observed GFP+ cells that migrated to the other side of the cord.
(C–E) The majority of GFP+ MGE cells were located in deep laminae (III-V).
(F) MGE cells extended long processes throughout the spinal cord. Scale bar equals 200 mm in (A) and (C); 50 mm in (B), (D), and(E); and 25 mm in (F).
See also Figure S1.
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GABA Precursor Transplants Treat Neuropathic Painbehavioral consequences of transplanting MGE cells in mouse
models of inflammatory and nerve injury-induced pain. We
report that MGE cells survive outside of the forebrain, retain
features of cortical interneurons, integrate into host spinal cord
circuitry, and promote an almost complete reversal of the
mechanical hypersensitivity generated by the nerve but not
tissue injury.
RESULTS
Cortical Inhibitory Precursor Cells Grafted into the Adult
Spinal Cord Differentiate into GABAergic Interneurons
We first asked whether the spinal cord environment was suffi-
cient to promote survival of the MGE cells transplants. To this
end, we used MGE cells that express green fluorescent protein
(GFP) under the control of the Gad1 (GAD67) promoter (Tama-
maki et al., 2003). In these mice, GAD+/GABAergic MGE cells
constitutively express GFP. Figures 1A–1B illustrate expression
of GFP in the spinal cord of naive, noninjured adult mice, 1 day
after transplantation of MGE cells into the dorsal horn. Most
transplanted GFP+ cells formed an aggregate at or near the
injection site, with some cells dispersed along the needle track.
Isolated cells were occasionally detected at a distance from the
heart of the injection site. In contrast, 1 month after transplanta-
tion, we observedGFP+ cells in both the dorsal and ventral horns
of the spinal cord. The transplanted cells had extensive and
ramified processes (Figures 1C–1F). We estimate that 2.7%
of transplanted MGE cells survived 1 month after transplantation
(1380 ± 478 cells per animal, n = 5). However, given the likelihood
that many cells were lost in the course of injection (cells remain-664 Neuron 74, 663–675, May 24, 2012 ª2012 Elsevier Inc.ing in the injection pipette, cell death in the course of the injec-
tion, cells trapped in the pia, etc.), it is likely that theMGE survival
rate is significantly underestimated. The majority of the GFP+
cells (71%) were located in the deep dorsal horn of the spinal
cord (laminae III-V), over 2.5 mm of the rostro-caudal lumbar
enlargement, all ipsilateral to the injection side.We did not detect
anyGFP+ cells in the thoracic or cervical spinal cord. Most GFP+
cells colabeled for NeuN, a marker of neurons (89.4% ± 2.7%,
Figures 2A–2C), but none for Iba1, a marker of microglia (Figures
2D–2F), or glial fibrillary acid protein (GFAP), a marker of astro-
cytes (Figures 2G–2I), indicating that the vast majority of MGE-
derived cells differentiated into neurons. By following the grafted
cells from 1 to 5 weeks after transplantation, we conclude that it
takes at least 2 weeks for the MGE-derived cells to acquire
a neuronal (NeuN+) phenotype (Figures 2J–2L).
The majority of the GFP+ MGE cells expressed markers of
subpopulations of cortical GABAergic interneurons, including
GABA (75.1% ± 9.6%, Figures 3A–3C), neuropeptide Y (NPY;
33.4% ± 9.1%, Figures 3D–3F), parvalbumin (PV; 22.2 ± 2.3%,
Figures 3G–3I), and somatostatin (40.1% ± 4.1%, Figures 3J–
3L). The presence of somatostain (SST)-GFP-positive neurons
is of particular interest as this neurochemical phenotype is char-
acteristic of a large percentage (40%) of MGE-derived cortical
GABAergic interneurons (Alvarez-Dolado et al., 2006). By
contrast, GABA does not colocalize with SST in spinal cord inter-
neurons; SST in fact marks a subpopulation of excitatory inter-
neurons (Yasaka et al., 2010). These results provide evidence
that the environment of the spinal cord does not alter the differen-
tiation of MGE-derived cells into phenotypes similar to those
observed in cortex. Taken together, these results indicate that
Figure 2. MGE-Derived Cells Differentiate into
Neurons
(A–C) One month after transplantation, most GFP+ (green)
MGE cells expressed NeuN (red), a marker of neurons.
(D–F) GFP+ (green) MGE cells did not express Iba1 (red),
a marker of microglia, or GFAP (G–I; red), a marker of
astrocytes.
(J and K) In contrast, 1 week after transplantation, MGE
cells did not co-stain for NeuN (red). Arrows point to
examples of NeuN-GFP+, double-labeled cells. Scale bar
equals 50 mm.
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GABA Precursor Transplants Treat Neuropathic PainMGE transplants are viable in a foreign tissue environment (spinal
cord versus cortex) and the majority of grafted cells differentiate
into GABAergic neurons, which recapitulate the normal hetero-
geneity of cortical (but not spinal) GABAergic interneurons.
As peripheral nerve injury induces a plethora of changes in the
dorsal horn, including a profound activation of potentially phago-
cyticmicroglia,wenext comparedMGEgraft survival in uninjured
mice and others that underwent partial nerve injury (spared nerve
injury, SNI). Survival rate of MGE cells in SNI animals (1.3%;
667 ± 267 cells per animal, n = 5) was in fact significantly lower
(50% less) than in naive animals. However, we found that there
were no significant differences in the neurochemical phenotype
of surviving cells in intact and injured animals (data not shown).
To determine whether the peripheral nerve injury contributed to
the lower recovery of transplanted neurons, we used TUNEL
staining to monitor apoptosis of transplanted neurons at 1 and
4weeksafter transplantation.Consistentwith the report ofMoore
et al. (2002), althoughwe recorded a fewTUNELpositive neurons
at these time points, nonewereGFP-positive (Figure S1 available
online). We conclude that cell death, at least via apoptosis, is
neither the major contributor to the limited recovery of trans-Neuron 74planted neurons nor the major contributor to
the further reduction recorded in nerve-injured
animals.
Integration of Cortical Inhibitory
Precursor Cells into Host Circuitry:
Presynaptic Inputs
We next addressed the extent to which the MGE
cells integrate into and make connections with
the spinal cord host circuitry. To determine
whether the transplanted cells are the targets of
primary sensory neurons, we transplanted the
MGE cells into the spinal cord of our ZW trans-
genic mouse line. In ZW mice, expression of the
transneuronal tracer wheat germ agglutinin
(WGA) can be induced by Cre recombination in
sensory neurons (Bra´z and Basbaum, 2008;
Bra´z et al., 2002, 2005). We crossed the ZW
micewithperipherin-Cremice (ZW-Per) to induce
WGA expression in a mixed (large- and small-
diameter) afferent population of dorsal root
ganglion (DRG) neurons (Zhou et al., 2002). If
the transplanted MGE cells receive inputs from
primary sensory neurons, then we should detecttransneuronal transfer of WGA from the sensory neurons to the
MGE-transplanted cells (Figures S2A–S2B). Figure 4 illustrates
that this is indeed the case. TheWGA is produced inDRGneurons
and transported into postsynaptic spinal cord neurons (Figures
4A–4D). Double-labeling experiments with antibodies against
GFP and WGA revealed that MGE-derived cells (arrows, Figures
4E–4F) were among the WGA-positive spinal cord neurons.
To determine whether a particular subpopulation of sensory
neurons communicates with the MGE transplants, we used our
recently described ZWX line (Bra´z and Basbaum, 2009), in which
it is possible in the adult to target expression of the tracer to
subsets of afferents by peripheral nerve injury. To target expres-
sion of the tracer to DRG neurons with myelinated axons, we
took advantage of the fact that NPY is expressed in these
neurons but only after peripheral nerve section (Noguchi et al.,
1993). In these studies, we made injections of MGE cells into
the spinal cord of ZWX mice crossed with NPY-Cre mice (De-
Falco et al., 2001). One month after transplantation, we trans-
ected the sciatic nerve so as to induce WGA expression in the
NPY subset of sensory neurons. Figures 4G–4I show that tran-
section of the sciatic nerve in the adult indeed induced high, 663–675, May 24, 2012 ª2012 Elsevier Inc. 665
Figure 3. MGE-Derived Neurons Assume
a GABAergic Phenotype
MGE-derived cells (green) coexpressed markers (red) of
cortical GABAergic interneurons, including GABA (A–C),
neuropeptide Y (NPY, D–F), parvalbumin (PV, G–I), and
somatostatin (SST, J–L). Arrows point to examples of
double-labeled cells. Scale bar equals 50 mm.
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GABA Precursor Transplants Treat Neuropathic Painlevels of WGA expression in NF200+ (a marker of myelinated
axons) DRG neurons (1 week posttransection). As expected,
subsequent transport of the WGA tracer to the spinal cord pre-
dominated in deeper laminae III-V of the dorsal horn (Figure 4J),
a major termination zone for cutaneous NPY-expressing DRG
neurons. As for the ZW-Per crosses, the MGE transplants were
also among the spinal neurons that had taken up the WGA
(arrow, Figure 4K). We estimate that 32.5% ± 3.8% of MGE cells
contained the WGA tracer. We also observed WGA+, but not
GFP+, neurons that were enveloped by terminals that derive
from the MGE cells (arrowhead, Figure 4L). These studies
demonstrate that myelinated afferents, the great majority of
which respond to innocuous peripheral stimulation, make
connections with transplanted MGE cells and that MGE cells
also target circuits engaged by primary afferents.
Functionality of the MGE Cell Transplants
If the connections established between DRG neurons and MGE
grafts are, in fact, functional, then a peripheral stimulus should666 Neuron 74, 663–675, May 24, 2012 ª2012 Elsevier Inc.‘‘activate’’ the MGE transplants. Because the
transneuronal WGA studies revealed a myelin-
ated afferent fiber connection with MGE trans-
plants, we asked whether innocuous peripheral
inputs could activate grafted neurons. One
month after transplantation, MGE-transplanted
mice walked on a rotarod for 90 min, a condition
thatpredominantly engages low thresholdmech-
anoreceptive (myelinated) afferents (Neumann
et al., 2008; Figure S3). Consistent with the
results from the tracing studies, we found that
this nonnoxiousperipheral input inducedexpres-
sion of Fos in 18.6% ± 6.3% MGE cells (Figures
5A–5C).ThemajorityofFos+MGEcellspredomi-
nated in deeper laminae (III-V) and around the
central canal, a region that receives input from
myelinated muscle spindle and joint afferents.
We next asked whether a noxious chemical
stimulus (hindpaw injection of 1% formalin),
which engages both unmyelinated and myelin-
ated axons (Bra´z and Basbaum, 2010; Shields
et al., 2010), can activate the MGE cells. Fig-
ure 5B illustrates that the injection of formalin
evoked Fos in both host and GFP+ transplanted
neurons in the dorsal horn, ipsilateral to the
noxious stimulus (1 month posttransplantation;
Figures 5D–5I and S3). In the superficial dorsal
horn, where Fos+ neurons predominate, we
found that 34.6% ± 13.4% of MGE neurons ex-
pressed Fos. On the other hand, injection offormalin in the hindpaw of 1 week-transplanted mice, despite
inducing significant Fos in host neurons, did not evoke Fos in
the transplanted neurons (Figures 5J–5L). In fact, by following
the grafted cells from 1 to 4 weeks after transplantation, we
conclude that it takes at least 2 weeks for the MGE-derived cells
to respond to a peripheral noxious input, which coincides with
the time when they acquire a neuronal phenotype. Taken
together, these functional assays indicate that 1 month after
transplantation, presumptive GABAergic MGE neurons are
‘‘activated’’ by nonnoxious, as well as noxious, inputs and
confirm the existence of functional connections between primary
afferent neurons and transplants.
Integration of Cortical Inhibitory Precursor Cells into
Host Circuitry: Targets of the Transplanted Neurons
We next asked whether grafted cells made connections with
host spinal cord neurons. To this end, we genetically modified
the MGE cells to express both the WGA tracer and a reporter
gene, mCherry (mCh). We hypothesized that WGA-expressing
Figure 4. Transplanted MGE-Derived Neurons
Receive Inputs from both Myelinated and Unmy-
elinated Primary Afferent Neurons
(A–F) We transplanted MGE cells into the spinal cord of
mice that express the inducible transneuronal tracer WGA
(red) in a mixed, unmyelinated, and myelinated NF200+
(green) population of DRG neurons (A andC). In thesemice
WGA is released throughout the dorsal horn of the spinal
cord (laminae I–V), where it was taken up by local neurons
(arrows in D), including the MGE-derived cells (green, E
and F). Insets show high-magnifications of neurons from
(E) and (F).
(G–L) When we transplanted MGE cells into the spinal
cord of ZWX mice that expressed the WGA selectively
in myelinated DRG neurons (NF200+, G–I), we also de-
tected the transneuronal transfer of WGA (arrows in J),
including the MGE-derived cells (green, K). Here, most
WGA labeling was concentrated in deeper laminae (III-V),
where cutaneous myelinated primary afferents terminate
(compare WGA-labeling patterns in D and J). We also
observed WGA+, but not GFP-, neurons that were envel-
oped by terminals that derive from theMGE cells (L). Insets
show high magnifications of neurons from (K and L). Scale
bars equal 200 mm in (A)–(C) and (G)–(I), 100 mm in (D) and
(J), and 30 mm in (E), (F), (K), and (L).
See also Figure S2.
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GABA Precursor Transplants Treat Neuropathic Paintransplanted MGE cells will release the WGA tracer in the spinal
cord and that the tracer, in turn, will be taken up by neurons that
are connected with the grafted cells (Figures S2C–S2D). In these
studies, we generated a lentiviral vector that expresses both
WGA and mCh (Lenti-WmCh; Figures S4A–S4D) under the
control of the CMV enhancer. We infected the MGE cells with
Lenti-WmCh and transplanted them into the spinal cord of naive,
noninjured adult mice. Animals were killed 1 month after trans-
plantation, which provided sufficient time for MGE integration,
expression and release of the WGA by the transplanted cells,
and uptake of the tracer into cells of the host spinal cord.
Figure6 illustrates that transplantedLenti-WmCh-infectedMGE
cellswereviable in thespinalcord.Weestimate that35.2%±4.4%
ofMGE,GFP+cells expressed themChmarker, andamong these,
most (95.1% ± 2.1%) expressed the WGA, indicating that almost
all infectedMGEcells synthesized theWGA tracer.Within 2weeks
of transplantation, we also detected many WGA+, but not GFP+,
spinal neurons (Figures 6A–6C and S4), indicating that the WGANeuron 74was released and taken up by host (GFP)
neurons. Importantly, 23.4% ± 2.1% of these
WGA+ neurons were mCh (Figures 6D–6F).
Given that mCh labels infected neurons, WGA+
and mCh neurons correspond to host spinal
neurons that took up the WGA tracer after its
release from transplanted cells, not because
they express the WGA. These connections
always remainedon thesideof thecord ipsilateral
to the transplant. When the transplanted cells
were located in both dorsal and ventral horn, we
also found WGA transneuronal transfer to
presumptive motoneurons (Figure S4). Taken
together, we conclude that MGE cells integrateinto host spinal cord circuitry. They receive inputs from different
categories of primary afferents and establish connections with
neurons of the host spinal cord.
MGE Transplants Target Spinal Cord Projection
Neurons
Spinal cord projection neurons receive inputs from nociceptors
and transmit this information to the brain. It is thus of interest
to ask whether these projection neurons are targeted by trans-
plantedMGE cells. In this regard, it is significant that many trans-
neuronally labeled WGA+ cells in lamina I, which contains
projection neurons, were enveloped by axon terminals that
derived from the transplanted cells (Figure 4L). To assess directly
the connectivity between transplanted cells and projection
neurons, we examined whether the transplanted cells could be
labeled after retrograde transneuronal transport of pseudorabies
virus (PRV; Jasmin et al., 1997) from a major brainstem target of
spinal cord projection neurons., 663–675, May 24, 2012 ª2012 Elsevier Inc. 667
Figure 5. Transplanted MGE-Derived Neurons Are
Activated by Innocuous and Noxious Peripheral
Stimulation
(A–C) Walking for 90 min on a rotarod induced expression
of Fos (red) in MGE cells, indicating that innocuous
peripheral stimuli (in this case conveyed by myelinated
primary afferents) activate the MGE transplants.
(D–L) Hindpaw injection of formalin (1%) also induces
expression of Fos (red) in a large number of spinal cord
neurons, including GFP+ (green) MGE-derived neurons,
1 month after transplantation (D–I) but not at 1 week
posttransplantation (J–L). Arrows point to examples of Fos
and GFP+ double-labeled cells. Scale bars equal 50 mm in
(A)–(C) and (G)–(L) and 100 mm in (D)–(F).
See also Figure S3.
Neuron
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spinal cord projection neurons, namely, the external lateral para-
brachial nucleus (elPB), 1 month after they received an MGE
transplant. We then followed the retrograde transneuronal
spread of the PRV. If MGE cells contact projection neurons
that project to the elPB, then the PRV should not only retro-
gradely infect projection neurons of lamina I but also the MGE
cells that are upstream of the projection neurons (Figure 7A).
Indeed, 3 days after PRV infection, we detected a large number
of PRV-infected spinal cord neurons (Figures 7B–7D and S5).
These cells were concentrated in laminae I and II. We presume
that the cells in lamina II correspond to interneurons that targeted
the projection cells of lamina I (Jasmin et al., 1997). Furthermore,
virtually all PRV+ neurons in lamina I were extensively enveloped
by GFP+ processes, indicating that projection neurons of lamina
I receive inputs from MGE-transplanted cells. Of particular
interest, however, was the observation of a small number of
double-labeled GFP+/PRV+ cells (5.2% ± 3.1%; arrows in Figur-
es7E–7G) in lamina II, which we hypothesize correspond to MGE
cells that have engaged a circuit targeting the projection
neurons. As we previously showed, PRV only ‘‘travels’’ between668 Neuron 74, 663–675, May 24, 2012 ª2012 Elsevier Inc.interconnected neurons (Bra´z et al., 2009), indi-
cating that theMGE-transplanted cells can influ-
ence lamina I projection neurons and possibly
modulate the transmission of ‘‘pain’’ messages
to the brain.
Grafted MGE Cells Reverse the
Persistent Pain Produced by Peripheral
Nerve Injury
Wenext assessed the behavioral consequences
of transplanting MGE GABAergic neuronal
precursors into the spinal cord of adult mice, in
a standardmodel of nerve injury-induced neuro-
pathic pain. The spared nerve injury (SNI) model
is produced by transection of two of the three
branches of the sciatic nerve resulting in pro-
longed mechanical hypersensitivity (Shields
et al., 2003). One week after SNI, mice received
a suspension of MGE cells (transplanted group)
or medium alone (no cells, control group), ipsi-
lateral to the injury side. Mechanical thresholdswere recorded before (baseline) and once a week (for 4 weeks)
after transplantation. Figure 8A illustrates that 1 day after SNI,
there is a dramatic reduction of the mechanical threshold (von
Frey) ipsilateral to the injury side. In the control group (SNI
animals that received an injection of medium alone), the marked
mechanical allodynia persisted for the 1 month observation
period (blue line in Figure 8). By contrast, we observed a gradual
reduction of the SNI-induced mechanical allodynia in MGE-
transplanted animals (red line, Figure 8), with a complete reversal
by 1 month. A significant difference between control and MGE-
transplanted groupswas first detected 2weeks posttransplanta-
tion (23 days post-SNI), similar to the time necessary for theMGE
cells to differentiate into neurons (Figure 2), and presumably inte-
grate into the host circuitry. However, the magnitude of the
recovery continued to improve, and thresholds returned to pre-
injury baseline levels 4 weeks after transplantation.
In another group of animals, we recorded the baseline thresh-
olds of naive noninjured mice before (0.97 ± 0.25) and after
(1.01 ± 0.23) transplantation of MGE cells. With neither protocol
did the MGE cell transplantation cells alter baseline mechanical
thresholds in the absence of nerve injury.
Figure 6. Transplanted MGE-Derived Neurons
Establish Connections with Host Spinal Cord
Neurons
(A–C) We infected MGE cells with a lentivirus that
expresses the tracer WGA and the reporter mCherry
and transplanted them in naive adult mice. Two weeks
after transplantation, 30% of GFP+ (green, I) MGE cells
expressed WGA (red). Importantly, we detected WGA+/
GFP- (arrowheads in A–C) neurons and also WGA+/mCh
(arrows in D–F) neurons in the spinal cord of transplanted
mice, indicating that spinal cord neurons had taken up the
tracer after its release fromMGE cells (see also Figure S3).
Arrowheads in (D)–(F) point to examples of WGA+/mCh+
double-labeled cells. Scale bars equals 100 mm in (A)–(C)
and 50 mm in (D)–(F).
See also Figures S2 and S4.
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Several studies demonstrated that a peripheral nerve injury
reduces GABAergic signaling, including a reduction of the
expression of GAD, the biosynthetic enzyme for GABA (Moore
et al., 2002). Here, we used quantitative PCR to determine
whether MGE transplants alter GAD mRNA levels, relative to
those in nerve-injured animals, where a decrease was predicted.
For this analysis, we transplanted MGE cells 1 week after SNI
and assayed both GAD65 and 67 levels 1 week later. We chose
this time point as Moore et al. (2002) reported that GAD protein
levels were significantly reduced 2 weeks after nerve injury. Fig-
ure 8B demonstrates that compared to uninjured animals, nerve
injury induced a small but significant decrease in the spinal cord
levels of GAD65 mRNA, ipsilateral to the injury; GAD67 levels did
not differ. By contrast, in the MGE-transplanted group, we re-
corded significantly greater GAD65 (6.7%) and GAD67 (7.1%)
levels compared to levels in the medium-injected group.
However, GAD mRNA levels in the MGE-transplanted group
did not differ from those in the naive group. Taken together,
these results indicate that MGE transplantation does not signifi-
cantly raise basal GAD mRNA expression (in uninjured animals)
but that the transplant can overcome the decrease of GAD
mRNA (and presumptive inhibitory tone and consequent
mechanical hypersensitivity) triggered by peripheral nerve injury.
Grafted MGE Cells Are Not Effective in a Model of
Chemical Nociception Associated with Inflammation
Finally, we asked whether transplantation of MGE GABAergic
precursor neurons also has antinociceptive effects in a model
of the other major class of chronic pain, namely, a chemical no-
ciception pain model associated with inflammation. Hindpaw
injection of formalin produces significant inflammation of the
paw and two distinct phases of pain behavior, characterized
by flinching and/or licking of the paw. In this condition, GABA
transmission is not compromised and, in fact, GABAergic tone
may be increased in the dorsal horn in the setting of tissue injury
(Hossaini et al., 2010). In our studies, we injected 1% formalin
into the hindpaw 4 weeks after the mice had received a dorsalNeuron 74horn transplant (ipsilateral to the transplant).
Figure 8C illustrates that the transplant did not
reduce pain behaviors in either the first or thesecond phases of this test. There was a slight decrease at all
time points during phase II but the reduction was not statistically
significant. We conclude that mechanical allodynia in a standard
model of neuropathic pain, but not the pain behavior evoked
in a common chemical nociception model associated with
inflammation, can be reversed by spinal cord transplantation of
GABAergic precursor cells.
DISCUSSION
Here, we show that MGE GABAergic interneuron precursor cells
transplanted into the spinal cord of adult mice with peripheral
nerve injury integrate into the host circuitry and are functionally
engaged by different modes of afferent stimulation. The trans-
plants also significantly reduce the mechanical hypersensitivity
produced in a model of neuropathic pain, without altering base-
line thresholds (without nerve injury). On the other hand, MGE
transplants do not affect inflammatory pain. These findings indi-
cate that GABAergic precursor cells have the essential proper-
ties for a cell-based therapy, particularly when loss of inhibitory
control is a major contributor to the clinical condition. This
approach differs from traditional pharmacological approaches
to pain therapy in twoways: (1) transplantation provides a contin-
uous and local delivery of inhibitory neurotransmitters, which not
only recapitulates more closely the endogenous condition, but
also avoids many of the adverse side effects associated with
systemically administered drugs. (2) Transplantation is poten-
tially disease modifying (i.e., it is directed at the underlying
etiology of the persistent pain, namely loss of GABAergic inhib-
itory controls).
Using the genetically engineered ZW and ZWX mice that
express the anterograde transneuronal tracer WGA, as well as
viral retrograde transneuronal tracers, we demonstrate that
MGE cells integrate into the host spinal cord circuitry. MGE cells
established connections with both primary afferent neurons and
postsynaptic elements of the circuitry, throughout the dorsal
horn, including projection neurons of lamina I. But perhaps
more importantly, we showed that these connections are, 663–675, May 24, 2012 ª2012 Elsevier Inc. 669
Figure 7. Transplanted MGE-Derived Neurons Integrate into Spinal Cord Circuits that Engage Lamina I Projection Neurons
(A) Injection of the retrograde transneuronal viral tracer pseudorabies (PRV, red) in the external lateral parabrachial nucleus (elPB; left panel) results in infection of
spinal cord projection neurons that target the elPB (projection neurons ‘‘become’’ red; middle panel). Subsequent retrograde transfer of PRV labels spinal cord
neurons that are upstream of the infected projection neurons (spinal neurons, including GFP+ (green) MGE cells, ‘‘become’’ red; right panel).
(B–D) PRV+ (red) projection neurons of spinal cord lamina I (arrows) and PRV+ interneurons of laminae II-III (arrowheads). Note the extensive arborization of
GFP-positive terminals around retrogradely PRV-labeled neurons (D, inset; see also Figure S5).
(E–G) MGE-transplanted cells (green) are among the cells that are retrogradely infected by PRV (red), indicating that MGE cells have integrated into a neuronal
circuit that influences projection neurons of lamina I. Arrowheads in E point to retrogradely infected PRV+/GFP- spinal cord interneurons. Arrows point to
examples of PRV+/GFP+ double-labeled cells. Arrowhead scale bars equal 100 mm in (B)–(D) and 50 mm in (E)–(G).
See also Figure S5.
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well as nonnoxious, peripheral stimuli. Although we cannot
distinguish between mono- and polysynaptic primary afferent
activation of the transplanted neurons, our study provides the
most direct assessment of the extent to which transplanted cells
integrate into the host spinal cord circuitry and begins to define
the types of afferents that engage the transplanted neurons and
the time course of the integration. It is of particular interest that
some MGE-derived neurons were located postsynaptic to
myelinated (presumably Ab) DRG neurons. This connection likely
drives a low threshold mediated inhibitory control, which is one
of the major postulates of the gate control theory of pain, which
emphasized large fiber-mediated inhibition of the transmission
of nociceptive message (Melzack and Wall, 1965).
The observation that MGE cells receive functional inputs in
naive noninjured adult animals is of particular interest. Indeed,670 Neuron 74, 663–675, May 24, 2012 ª2012 Elsevier Inc.integration of the MGE cells into local spinal circuits provides
evidence that elements of the circuit (primary afferents and/or
spinal neurons) have the ability to extend new processes (e.g.,
sprout) and form new synapses in the absence of peripheral
nerve injury. It is, of course, possible that the transplantation it-
self produces an injury that induces sprouting of the afferents.
It is also possible that the input to MGE cells is derived from
regeneration of the central branch of sensory neurons that
were injured during the transplant procedure. Indeed, in the
setting of peripheral nerve injury, regeneration, particularly of
large diameter axons, may be enhanced (Neumann et al., 2002).
We demonstrated that MGE-transplanted cells make connec-
tions with a large number of spinal cord neurons. Importantly,
even when the MGE cells were located ventral to lamina III, the
entire mediolateral width of the superficial and dorsal horn was
often encompassed by MGE-derived axonal arbors. The latter
Figure 8. MGE-Derived Neurons Reverse the Mechanical Allody-
nia Produced by Partial Nerve Injury but Do Not Affect Inflamma-
tory Pain
(A) Changes of mechanical threshold (allodynia; von Frey test) after partial
sciatic nerve injury (SNI) and after MGE transplantation are reported as percent
of pre-SNI baseline ± SEM. One day after SNI, there is a dramatic reduction of
the mechanical threshold of the hindpaw ipsilateral to the injury. In SNI animals
that only received cell medium, the marked mechanical allodynia persisted
throughout the 4 week observation period (blue line). In contrast, there was
a gradual reduction of the mechanical allodynia in MGE-transplanted animals
(red line), with a complete reversal at 1month (day 37 post-SNI). The difference
between mechanical thresholds of the two groups was statistically significant
2 weeks after transplantation.
(B) Compared to naive animals, we found that after SNI, there is a small but
significant decrease in the spinal cord levels of GAD65 but not of GAD67
mRNA ipsilateral to the nerve injury. In the MGE-transplanted group, both
GAD65 and GAD67 levels were significantly greater than those in medium-
injected nerve-injured mice. However, the levels of GAD mRNA in the MGE
transplanted and naive mice did not differ. Asterisks (*) indicate statistically
significant differences between groups, with * = p < 0.05 and ** = p < 0.01.
(C) Transplanting MGE cells did not reduce pain behaviors in the formalin test.
Although there was a slight decrease throughout the second phase of testing,
the effect was not statistically significant.
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projection neurons of lamina I. Hence, MGE cells target and
can influence a large variety of spinal cord neurons, including
many that respond to noxious stimuli. We conclude that MGE-
derived transplants do not serve merely as ‘‘cell-based chemical
pumps,’’ which is characteristic of other cell-based approaches
(e.g., intrathecal injection of adrenal chromaffin cell or other
precursor cells). Rather, by integrating into functional circuits,
MGE cells overcome a functional deficit that reverses a critical
etiology (i.e., defects in endogenous inhibition) of the persistent
pain (Eaton et al., 1999; Hao et al., 2005; Liu et al., 2004; Sagen
et al., 1990; Winnie et al., 1993; Yu et al., 1998).
Our results go considerably beyond previous efforts to over-
come the loss of GABAergic inhibition. For example, both
trigeminal injection of an adenoviral vector expressing the
GABA synthesizing enzyme, GAD65, or peripheral injection of
an HSV vector expressing GAD67 had antinociceptive effects
in models of facial pain (Vit et al., 2009) and spinal nerve ligation
(Hao et al., 2005), respectively. Intrathecal (Vaysse et al., 2011)
and intraspinal (Mukhida et al., 2007) injection of human cell lines
engineered in vitro to express GABA also attenuated nerve
injury-induced mechanical allodynia in the rat. However, in
none of these cases was there evidence for integration of the
GABAergic cells into the host. Furthermore, embryonic human
progenitor cells, whether immortalized or not, require expansion
in vitro. With increasing time in culture, i.e., after multiple
passages, the properties of the cells can change, which reduces
the likelihood of their differentiating into neurons (Jain et al.,
2003). Furthermore, as many neural stem cells maintain their
proliferative potential after transplantation (Mukhida et al.,
2007), the potential for tumor development cannot be ignored.
Finally, and of particular importance to long-term pain manage-
ment, is that transplants reported to date have a relatively short
survival, which reduces their clinical utility. In contrast, we show
that MGE cells have the essential properties for a cell-based
therapy: long survival rate, stability and safety, differentiation
into functionally integrated mature interneurons, and presump-
tive rescue of GABAergic inhibitory control.
We demonstrate that the spinal cord environment is sufficient
to promote survival (even in the context of a peripheral nerve
injury) and, perhaps more importantly, integration of trans-
planted precursor cells. Interestingly, transplanted MGE cells
recapitulated the normal heterogeneity of cortical (but not spinal)
GABAergic neurons, indicating that the phenotype of the MGE
cells is predetermined. Apparently, MGE cells are not influenced
by the local environment, at least with respect to their neuro-
chemical makeup. On the other hand, despite their rather rigid
differentiation program, these cortically derived cells clearly
adapt and thrive in a novel environment. The time course anal-
yses showed that it takes at least 2 weeks for the MGE cells to
acquire a neuronal (NeuN+) phenotype and to respond to
a peripheral stimulus (i.e., express Fos). This time point corre-
sponds remarkably well with the time where we first recorded
a significant difference in the mechanical thresholds between
control andMGE-transplanted groups. This tight temporal corre-
lation between integration of the transplanted cells and reduction
of the mechanical allodynia indicates that integration is essential
for the recovery. Interestingly, although we recorded a reductionNeuron 74, 663–675, May 24, 2012 ª2012 Elsevier Inc. 671
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detected, there was no correlation between the number of
surviving MGE cells and their anti-allodynic effect, i.e., animals
with the highest number of MGE cells did not always have the
greatest recovery of mechanical threshold. This finding suggests
that there may be a threshold above which the number of trans-
planted MGE cells may be less relevant to achieve a functional
improvement.
Importantly, despite the fact that systemic or direct spinal
administration of GABA agonists is antinociceptive in various
inflammatory pain models, including the formalin test (Knabl
et al., 2008; Vit et al., 2009), transplantation of GABAergic
precursor neurons did not reduce pain behaviors induced by
hindpaw injection of formalin. This differential effect of MGE
transplantation on nerve versus tissue injury-induced pain
suggests that the transplants recapitulate theGABAergic circuits
that were altered by nerve injury. In other words, the transplants
are disease, rather than symptom modifying.
Recent studies reported that nerve injury-induced activation of
microglia can lead to a BDNF-mediated shift in the chloride
gradient of projection neurons in lamina I (and likely in deep
dorsal horn), such that GABAergic inputs nowbecome excitatory
(Coull et al., 2003; De Koninck, 2007; Price et al., 2009).
However, our findings provide evidence that enhancing
GABAergic function by transplantation is clearly antinociceptive,
not pronociceptive, in the setting of nerve injury. Thus, any
changes that result in a GABAergic excitatory action secondary
to changes in chloride gradients (which likely occur only in
a subset of neurons) can clearly be overcome by the transplant.
Again, this points to the transplants reestablishing normal
GABAergic circuitry, rather than serving as a generalized source
of GABA, as would occur with a pump.
Of course, we cannot be certain that the antinociceptive effect
of the transplants is GABA-mediated. However, because almost
75% of MGE cells differentiated into GABAergic neurons, it is
likely that this is the case. The fact that the MGE transplants
normalized GAD65 mRNA levels, which decrease after periph-
eral nerve injury and increased GAD67 mRNA levels, is consis-
tent with our proposal that the therapeutic effect of MGE
transplants is GABA-mediated. It is, however, also possible
that release of neurotransmitters/neuromodulators other than
GABA contribute to the observed behaviors. For example, the
inhibitory neurotransmitter glycine, which co-occurs in some
spinal cord (but not cortical) GABAergic neurons (Mackie et al.,
2003; Todd et al., 1996), could provide a significant source of
inhibition. As the transplanted cells appear to retain their cortical
makeup (e.g., they continue to express somatostatin, which is
not found in spinal cord GABAergic interneurons), we favor the
hypothesis that the inhibition derives from GABAergic, rather
than glycinergic control.
As previous studies found that pharmacological treatment
with GABAergic agonists can produce long-term amelioration
of nerve injury-induced pain conditions (Knabl et al., 2009) in
animals as well as humans, it will be of interest to follow the
MGE-transplanted animals for longer periods of time. Such
studies will determine whether there is further improvement or
deterioration/tolerance, whether some animals show delayed
anti-allodynic effects and whether animals eventually develop672 Neuron 74, 663–675, May 24, 2012 ª2012 Elsevier Inc.an analgesic phenotype (i.e., have mechanical thresholds
greater than baseline).
Finally, it is of interest to ask whether transplants, such as
these, might have clinical utility. Unquestionably, there are
many neuropathic pain conditions where the nerve damage is
limited and the pain presumably arises from pathophysiological
changes (including GABAergic dysfunction) in localized regions
of the cord (as in complex regional pain syndrome and even
phantom limb pain) or in the trigeminal nucleus caudalis (as in
trigeminal neuralgia and other facial pain conditions). On the
other hand, in individuals with diabetic neuropathy or chemo-
therapy-induced polyneuropathy, the nerve damage is likely
widespread. Nevertheless, even in the majority of these individ-
uals the most debilitating pains occur in the extremities (hands
and feet). Thus, a focal (lumbar or cervical enlargement trans-
plant) that can overcome a GABAergic circuit abnormality may
also be beneficial. A great advantage of this approach, of course,
is that the adverse and typically dose-limiting side effects asso-
ciated with systemic drug administration can be avoided.
EXPERIMENTAL PROCEDURES
Mouse Lines
All experiments were reviewed and approved by the Institutional Care and
Animal Use Committee at the University of California San Francisco. MGE cells
were dissected from transgenicmice that expressGFP under the control of the
GAD67 promoter (Gad1tm1.1Tama; Tamamaki et al., 2003). All transplants were
performed onmale mice (6–8 weeks old) with the same genetic background as
the MGE donors (CD1xC57BL6/J). The ZW and ZWX mice were described
previously (Bra´z and Basbaum, 2009; Bra´z et al., 2002). To generate double
transgenic ZWX-NPY mice, we crossed the ZWX mouse with mice that
express Cre recombinase in NPY expressing neurons (DeFalco et al., 2001;
gift of Dr. Jeffrey Friedman). To generate Per-ZW mice, we crossed the ZW
mice with Peripherin-Cre mice (Jackson Laboratory, Bar Harbor, ME, USA;
Zhou et al., 2002).
Sciatic Nerve Injury
To produce mechanical hypersensitivity in a model that mimics a neuropathic
pain condition, we used the spared nerve injury (SNI) model as described
previously (Shields et al., 2003). In a different series of transplanted mice, we
induced expression of the WGA tracer in sensory neurons of ZWX-NPY mice
as described previously (Bra´z et al., 2009), 1 month after transplantation.
Transplantation of Medial Ganglionic Eminence Cells
The methods used to transplant MGE cells have been described previously
(Alvarez-Dolado et al., 2006). For transplantation, 6- to 8-week-old mice (naive
or 1 week after SNI) were anesthetized by an intraperitoneal injection of ket-
amine (60 mg/kg)/xylazine (8 mg/kg). We then made a dorsal hemilaminec-
tomy at the level of the lumbar enlargement to expose two segments
(1.5–2 mm) of lumbar spinal cord, after which the dura mater was incised
and reflected. A cell suspension containing 5 3 104 MGE cells was loaded
into a glassmicropipette (prefilled with mineral oil). Themicropippete was con-
nected to a micro-injector mounted on a stereotactic apparatus. The cell
suspension injections were targeted to the dorsal horn, ipsilateral to the nerve
injury. The control groups were injected with an equivalent volume of DMEM.
The wound was closed and the animals were allowed to recover before they
were returned to their home cages. Animals were killed at different times post-
transplantation (from 1 to 5 weeks). Importantly, none of the transplanted
animals exhibited signs of motor impairment. Furthermore, mice in both
groups walked on a rotating rod for the 90 min observation period.
For some anatomical studies, naive mice were transplanted with MGE cells
that were geneticallymodified so as to express theWGA tracer. In these exper-
iments, freshly dissociated MGE cells were incubated with a Lenti-WGAmCh
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washes, the cells were pelleted, resuspended in DMEM, and kept on ice until
transplantation.
Antibodies
Rabbit anti-WGA (1:50,000; Sigma-Aldrich, St. Louis, MO, USA), mouse anti-
NF200 (1:10,000; Sigma-Aldrich), rabbit anti-GFP (1:2,000; Molecular Probes,
Eugene, OR, USA), chicken anti-GFP (1:2,000; Abcam, Cambridge, UK), rabbit
anti-PRV (1:20,000; gift from Dr. Lynn Enquist), mouse anti-PV (1:2,000;
Sigma-Aldrich), rabbit anti-Fos (1:5,000; Oncogene, Carpinteria, CA, USA),
rabbit anti-GFAP (1:20,000; Dako, Carpinteria, CA, USA), rabbit anti-Iba1
(1:1,000; Wako, Richmond, VA, USA), rabbit anti-dsRed (1:500; Clontech,
Mountain View, CA, USA), rat anti-SST (1:400; Millipore, Billerica, MA, USA),
mouse anti-GABA (1:4,000; Sigma-Aldrich), mouse anti-NPY (1:2,000; gift
from Dr. J.M. Allen, London, UK), and mouse anti-NeuN (1:2,000; Chemicon,
Temecula, CA, USA).
Immunohistochemistry
Immunohistochemistry was performed as previously described (Bra´z and
Basbaum, 2008). Sections were viewed with a Nikon Eclipse fluorescence
microscope, and images were collected with a Zeiss camera (Axiocam, Ober-
kochen, Germany). High-resolution confocal images taken on a Zeiss confocal
confirmed that we are examining intracellular label (0.8 mm optical sections).
Brightness and contrast were adjusted using Adobe Photoshop (version 6.0;
San Jose, CA, USA).
Cell Counts and Quantification
Labeled cell bodies were counted from digitized images. The percentage of
surviving MGE cells was determined by counting all GFP+ cell bodies in 10
spinal cord sections (separated by 100 mm). The average number of GFP+ cells
per section was then extrapolated to the total number of spinal cord sections
that contained GFP+ cells, using the formula Total GFP = A 3 B/2 (where A is
the average number of GFP+ cells per section and B is the total number of
spinal cord sections containing GFP+ cells; given the thickness of the spinal
cord sections and the size of the MGE cells, we only included every other
section so that cells were not counted twice). For example, if in one trans-
planted animal, the average number of GFP+ cells per section was 15 and
we detected GFP+ cells over 100 serial spinal cord sections, then the total
number of GFP+ cells per animal would be 153 (100/2) = 750. The percentage
of cell survival was then estimated as 100 3 (totalGFP)/(number of trans-
planted cells). Five animals per group were counted.We estimate that 1 month
after transplantation, naive animals had on average 22 GFP+ cells per spinal
cord section, whereas SNI-transplanted animals had only 12.
The percentage of transplanted GFP+ MGE cells expressing a second
marker (NeuN, Iba1, GFAP, Fos, WGA, dsRed, GABA, PV, SST, or NPY) after
transplantation was calculated from ten coronal spinal cord sections (sepa-
rated by 100 mm). At least 100GFP+MGE cells were analyzed for eachmarker,
in each animal (n = 3). Spinal cords were analyzed at 1 and 2 weeks after trans-
plantation for the NeuN, Iba1, and GFAP markers and at 1 month after trans-
plantation for all other markers. The percentage of double-labeled neurons
(marker+ and GFP+) was calculated by dividing the number of double-labeled
neurons by the number of single GFP-labeled neurons3 100. Values are given
as mean ± standard deviation (SD).
Quantitative PCR
Mice were transplanted with medium (n = 6) or MGE cells (n = 5) 1 week after
SNI and killed 1 week after transplantation (i.e., 2 weeks after the nerve injury).
Naive (uninjured) mice (n = 3) were also used as controls. The lumbar spinal
cord that contained the transplant was rapidly dissected, and a comparable
region was dissected from naive animals after which the cord was divided
into ipsilateral and contralateral halves (containing both dorsal horn ventral
tissue). We used the RNeasy Minikit from Qiagen to extract mRNA, after which
200 ng of purifiedmRNAwas reverse-transcribed into cDNA using Superscript
II (Invitrogen, Carlsbad, CA, USA). The mRNA levels for GAD65, GAD67, and
b-actin were quantified with a Realplex2 real-time PCR system (Eppendorf,
Hamburg, Germany) using SYBRGreen PCRMaster Mix (Applied Biosystems,
Warrington, UK). Ratios of GAD65 and GDA67 to b-actin mRNA werecompared and analyzed by a two-way ANOVA followed by a Bonferroni post
hoc test. Asterisks (*) indicate statistically significant differences between
groups, with * = p < 0.05 and ** = p < 0.01.
Behavioral Analyses
Mechanical sensitivity was assessed by placing animals on an elevated wire
mesh grid and stimulating the hindpaw with von Frey hairs. We used the
up-down paradigm (Chaplan et al., 1994) to define threshold. Animals were
tested three times, once every other day before surgery to determine baseline
threshold and once 2 days after surgery, to assess the magnitude of the
mechanical allodynia. Only animals that displayed at least a 50% drop of the
mechanical withdrawal threshold were included in the MGE transplantation
(transplanted group) or the medium injection (control group) groups. Behav-
ioral testing took place on days 7, 14, 21, and 28 after MGE/medium injections.
For the behavioral tests, the investigator was blind to treatment (cell medium or
MGE injection). Prior to analyzing the behavioral results, MGE-transplanted
animals were killed, and then the spinal cord was immunostained for the pres-
ence of GFP+ cells in the spinal cord. Only successfully transplanted animals
(defined as containing at least one GFP+ cell per section) were included in the
MGE-transplanted group and their behavior subsequently analyzed. Impor-
tantly, the investigator performing this anatomical analysis was not the inves-
tigator who performed the behavior analysis and thuswas blind to the behavior
results. Transplanted animals from which no GFP-immunoreactive cells were
detected were included in a ‘‘failed transplant’’ group. As the mechanical
thresholds of the ‘‘failed transplant’’ and the medium-injected control groups
were not significantly different, results from the ‘‘failed transplant’’ animals
were not included in the statistical analysis.
In another set of experiments, we injected 10 ml of a 1% formalin solution
(Sigma-Aldrich, St. Louis, MO, USA) into the hindpaw of medium or MGE-
cell-transplanted mice, ipsilateral to the transplanted side. We scored the
mice for the total time spent flinching or licking the injected hindpaw (in
5 min bins). The behavioral scores were made by an experimenter blinded to
treatment group. Only after the animals were defined as belonging to the
MGE transplant, ‘‘failed transplant,’’ or medium transplant group were the
behavioral results analyzed.
Statistical Analyses
Behavioral data are expressed as mean ± SEM (standard error of the
mean), where n represents the number of mice tested. Raw data of the
mechanical withdrawal thresholds obtained in the course of the study
were analyzed by a two-way ANOVA followed by a Tukey post hoc test.
Asterisks (*) indicate statistically significant differences between groups,
with * = p < 0.05, ** = p < 0.01, and *** = p < 0.001.
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